RESMED INC

NYSE: RMD (ResMed Inc.)

Last update: 18 hours ago

237.85

-0.34 (-0.14%)

Previous Close 238.19
Volume 1,454,603
Price / Earnings (Forward) 19.83
Price / Sales 6.07
Price / Book 5.66
52 Weeks Range
180.27 (-24%) — 277.67 (16%)
TTM Dividend Yield 1.08%
Profit Margin 26.15%
Operating Margin (TTM) 33.00%
Diluted EPS (TTM) 8.92
Quarterly Revenue Growth (YOY) 7.90%
Quarterly Earnings Growth (YOY) 21.50%
Total Debt/Equity (MRQ) 15.14%
Current Ratio (MRQ) 3.41
Operating Cash Flow (TTM) 1.65 B
Levered Free Cash Flow (TTM) 1.20 B
Return on Assets (TTM) 14.01%
Return on Equity (TTM) 25.81%

AIStockmoo Score

0.2
From our AI Insight report's view of expected return against risk. info NA
Priced high for its earnings growth. info
The price implies earnings growth of 18.5% a year; the business can fund about 15.0% a year. info
Cheaper than its usual valuation. info
Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info
Earns well above its cost of capital. Returns on capital rising. info
From our AI technical analysis of the chart. info NA
No clear trend over the past year. Somewhat below its 52-week high. info
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. A recent move above resistance has not been confirmed. info
Candle Patterns info NA
Above its medium-term trend line. info
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Several insiders net selling recently. Price is above where insiders sold. info
Institutions net -4.56% of shares in their latest 13F filings: 414 holders increased, 481 decreased (quarter to 30 Sep 2026). info
Market environment cautious. info
Sector outperforming the market.
The pillars disagree, so the score is softened.
Price is high against its 52-week average. info
Short-term momentum fading. info
Price is between support and resistance. info
Final Score 0.22
Show all

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Mixed Mixed
Medical Instruments & Supplies (Global) Mixed Mixed
Stock ResMed Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
RMD - 1.08% - 5.66
BDX - 2.20% - 2.41
WST - 0.37% - 9.67
BLCO - - - 1.17
ALC - 0.49% - 1.64
STVN - 0.30% - 2.39

Select this tab to load the latest available analysis.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Mid Core
% Held by Insiders 0.78%
% Held by Institutions 65.16%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BLOOMER AARON - 238.53 -1,095 -261,190
DE WITTE JAN - 238.53 -60 -14,312
FARRELL MICHAEL J. - 237.47 -13,104 -3,111,767
FARRELL PETER C - 238.53 -169 -40,312
GILL HARJIT - 238.53 -36 -8,587
RIDER MICHAEL J - 238.53 -1,944 -463,702
Aggregate Net Quantity -16,408
Aggregate Net Value ($) -3,899,870
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 237.68
Name Holder Date Type Quantity Price Value ($)
RIDER MICHAEL J Officer 11 Nov 2026 Disposed (-) 1,944 238.53 463,702
GILL HARJIT Director 11 Nov 2026 Disposed (-) 36 238.53 8,587
DE WITTE JAN Director 11 Nov 2026 Disposed (-) 60 238.53 14,312
FARRELL PETER C Director 11 Nov 2026 Disposed (-) 169 238.53 40,312
BLOOMER AARON Officer 11 Nov 2026 Disposed (-) 1,095 238.53 261,190
FARRELL MICHAEL J. Officer 11 Nov 2026 Disposed (-) 8,111 238.53 1,934,717
FARRELL MICHAEL J. Officer 09 Nov 2026 Automatic sell (-) 4,993 235.74 1,177,050
FARRELL MICHAEL J. Officer 09 Nov 2026 Option execute 4,993 - -

Institutions

Institutional ownership: 80.42%

Positions Holders Shares
Increased 414 4,315,361
Decreased 481 10,303,418
New 115 481,103
Sold out 117 920,995

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

2 Positive 1 Negative 0 Neutral
Date Type Details
06 Nov 2026 Yahoo Finance Don’t Lose Sleep Over GLP-1s: Why ResMed Stock Is a Bargain
ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.
02 Nov 2026 Yahoo Finance ResMed: 3 Key Takeaways for Long-Term Investors
Manufacturing gains are lifting margins faster than revenue growth, signaling operational leverage ahead.
01 Nov 2026 Yahoo Finance What Sent ResMed Stock Lower?
For questions about this article or underlying research, email [email protected].
31 Oct 2026 Yahoo Finance RMD Q3 deep dive: product innovation and supply chain execution drive results amid evolving landscape
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.
30 Oct 2026 Yahoo Finance ResMed (RMD) Looks Fully Valued After Another Earnings Beat
ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools. ResMed’s share price has climbed 13.5% over the past month and 19.8%…
30 Oct 2026 Yahoo Finance ResMed (RMD) Q1 2027 Earnings Call Transcript
Sleep device revenue grew 6% as AI tools boost therapy compliance and partnerships expand.
30 Oct 2026 Yahoo Finance ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
30 Oct 2026 Yahoo Finance ResMed Inc. Q1 2027 Earnings Call Summary
Moby summary of ResMed Inc.'s Q1 2027 earnings call…
30 Oct 2026 Yahoo Finance What ResMed (RMD) Said on Its Q1 Earnings Call
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earning…
30 Oct 2026 Yahoo Finance RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
29 Oct 2026 Yahoo Finance ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.
29 Oct 2026 Yahoo Finance ResMed (RMD) Beats Q1 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
29 Oct 2026 Yahoo Finance ResMed: Fiscal Q1 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $418…
29 Oct 2026 Yahoo Finance Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basisQ1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1 Note: A webcast of Resmed’s…
29 Oct 2026 Yahoo Finance Ozlo Raises $22 Million Series B Led by Modi Ventures to Expand Its Sleep Technology Ecosystem
Funding will accelerate product development, sleep research, and new technologies addressing a broader range of sleep and nighttime health needs BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ozlo, the sleep technology company behind Ozlo Sleepbuds®, announced it has raised $22 million in Series B…
28 Oct 2026 Yahoo Finance Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026…
Show more
TTM Dividend Yield 1.08%
5Y Average Dividend Yield 0.72%
Payout Ratio 23.23%
Ex Date Announcement Date Payment Date Details
13 Feb 2025 30 Jan 2025 20 Mar 2025 0.53 Cash
07 Nov 2024 24 Oct 2024 12 Dec 2024 0.53 Cash
15 Aug 2024 01 Aug 2024 19 Sep 2024 0.53 Cash
08 May 2024 25 Apr 2024 13 Jun 2024 0.48 Cash
07 Feb 2024 24 Jan 2024 14 Mar 2024 0.48 Cash
08 Nov 2023 26 Oct 2023 14 Dec 2023 0.48 Cash
16 Aug 2023 03 Aug 2023 21 Sep 2023 0.48 Cash
10 May 2023 27 Apr 2023 15 Jun 2023 0.44 Cash
08 Feb 2023 26 Jan 2023 16 Mar 2023 0.44 Cash
09 Nov 2022 27 Oct 2022 15 Dec 2022 0.44 Cash
17 Aug 2022 11 Aug 2022 22 Sep 2022 0.44 Cash
11 May 2022 28 Apr 2022 16 Jun 2022 0.42 Cash
09 Feb 2022 27 Jan 2022 17 Mar 2022 0.42 Cash
09 Nov 2021 28 Oct 2021 16 Dec 2021 0.42 Cash
18 Aug 2021 05 Aug 2021 23 Sep 2021 0.42 Cash
12 May 2021 29 Apr 2021 17 Jun 2021 0.39 Cash
10 Feb 2021 28 Jan 2021 18 Mar 2021 0.39 Cash
10 Nov 2020 29 Oct 2020 17 Dec 2020 0.39 Cash
19 Aug 2020 05 Aug 2020 24 Sep 2020 0.39 Cash
13 May 2020 30 Apr 2020 18 Jun 2020 0.39 Cash
12 Feb 2020 30 Jan 2020 19 Mar 2020 0.39 Cash
06 Nov 2019 25 Oct 2019 12 Dec 2019 0.39 Cash
14 Aug 2019 26 Jul 2019 19 Sep 2019 0.39 Cash
08 May 2019 03 May 2019 13 Jun 2019 0.37 Cash
06 Feb 2019 25 Jan 2019 14 Mar 2019 0.37 Cash
07 Nov 2018 26 Oct 2018 13 Dec 2018 0.37 Cash
15 Aug 2018 03 Aug 2018 20 Sep 2018 0.37 Cash
09 May 2018 26 Apr 2018 14 Jun 2018 0.35 Cash
07 Feb 2018 23 Jan 2018 15 Mar 2018 0.35 Cash
08 Nov 2017 26 Oct 2017 14 Dec 2017 0.35 Cash
15 Aug 2017 01 Aug 2017 21 Sep 2017 0.35 Cash
09 May 2017 27 Apr 2017 15 Jun 2017 0.33 Cash
07 Feb 2017 23 Jan 2017 16 Mar 2017 0.33 Cash
08 Nov 2016 25 Oct 2016 15 Dec 2016 0.33 Cash
16 Aug 2016 28 Jul 2016 22 Sep 2016 0.33 Cash
17 May 2016 26 Apr 2016 16 Jun 2016 0.3 Cash
09 Feb 2016 21 Jan 2016 17 Mar 2016 0.3 Cash
17 Nov 2015 22 Oct 2015 17 Dec 2015 0.3 Cash
18 Aug 2015 30 Jul 2015 17 Sep 2015 0.3 Cash
19 May 2015 23 Apr 2015 18 Jun 2015 0.28 Cash
10 Feb 2015 22 Jan 2015 19 Mar 2015 0.28 Cash
18 Nov 2014 23 Oct 2014 18 Dec 2014 0.28 Cash
19 Aug 2014 31 Jul 2014 18 Sep 2014 0.28 Cash
16 May 2014 23 Apr 2014 17 Jun 2014 0.25 Cash
14 Feb 2014 23 Jan 2014 19 Mar 2014 0.25 Cash
15 Nov 2013 24 Oct 2013 18 Dec 2013 0.25 Cash
16 Aug 2013 01 Aug 2013 17 Sep 2013 0.25 Cash
17 May 2013 25 Apr 2013 18 Jun 2013 0.17 Cash
14 Feb 2013 24 Jan 2013 19 Mar 2013 0.17 Cash
16 Nov 2012 25 Oct 2012 18 Dec 2012 0.17 Cash
05 Sep 2012 02 Aug 2012 28 Sep 2012 0.17 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.530 1 0.22
2024 2.02 4 0.88
2023 1.84 4 1.07
2022 1.72 4 0.83
2021 1.62 4 0.62
2020 1.56 4 0.73
2019 1.52 4 0.98
2018 1.44 4 1.27
2017 1.36 4 1.61
2016 1.26 4 2.03
2015 1.16 4 2.16
2014 1.06 4 1.89
2013 0.840 4 1.78
2012 0.340 2 0.82
Show more

Recent Signals candle patterns and EMA crosses

▲ Golden cross 18 sessions ago · 22 Oct
Long term · EMA 50/200
The 50-day EMA crossed above the 200-day, a widely watched sign that the long-term trend has turned up.

Technical Setup Medium

Trend order
Slope
Entry
Volume
In an uptrend: the price is above its moving averages, and they are rising. It is close to them. A recent move above resistance has not been confirmed.
Nearest support: 226.75 – 237.30 · strong level
Nearest resistance: 236.57 – 240.17 · weak level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria